Mont-Saint-Guibert, Belgium - Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell therapies, today announced the selection of three abstracts for poster presentation at the upcoming 24th Congress of the European Hematology Association (EHA) in Amsterdam, The Netherlands, on June 13-16, 2019, including updated data from the THINK and DEPLETHINK Phase 1 trials evaluating the company’s autologous NKG2D-based CAR-T therapy CYAD-01 for the treatment of relapsed/refractory acute myeloid leukemia (r/r AML) and myelodysplastic syndrome (MDS).

Clinical Presentation

Title:          Updated Results from the Phase 1 Trials Assessing a NKG2D CAR T-Cell Approach in Relapsed/Refractory Acute Myeloid Leukimia and Myelodysplastic Syndrome Patients. Download the poster 

Abstract:    PS1212

Session:     Gene therapy, cellular immunotherapy and vaccination – Clinical

Date:         Saturday, June 15th

Time:         5:30 - 7:00 p.m. CEST (Poster Area)

 

Preclinical Presentations

Title:          Development of a Next Generation Allogeneic CAR-T Cell Platform Without Gene Editing. Download the poster.

Abstract:    PS1210

Session:     Gene therapy, cellular immunotherapy and vaccination – Biology & Translational   Research

Date:          Saturday, June 15th

Elevator pitch:   4:30 - 4:45 p.m. CEST (Hall G106)

Time:          5:30 - 7:00 p.m. CEST (Poster Area)

 

Title:           Modeling NKG2D-based CAR-T Cell Therapy in Animals with Acute Myeloid Leukemia. Download the poster

Abstract:     PS974

Session:      Acute myeloid leukemia - Biology & Translational Research

Date:          Saturday, June 15th

Time:          5:30 - 7:00 p.m. CEST (Poster Area)

Download press release(s)

Press release

112.79 Ko

Communiqué de presse

125.29 Ko

Celyad to Participate in Upcoming June 2019 Conferences

Next News

Celyad to Participate in Upcoming June 2019 Conferences